Online citations, reference lists, and bibliographies.
← Back to Search

A Randomized, Double-blind, Placebo-controlled Study Of Vortioxetine On Cognitive Function In Depressed Adults

R. McIntyre, S. Lophaven, C. Olsen
Published 2014 · Psychology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The efficacy of vortioxetine 10 and 20 mg/d vs. placebo on cognitive function and depression in adults with recurrent moderate-to-severe major depressive disorder (MDD) was evaluated. Patients (18–65 yr, N = 602) were randomized (1:1:1) to vortioxetine 10 or 20 mg/d or placebo for 8 wk in a double-blind multi-national study. Cognitive function was assessed with objective neuropsychological tests of executive function, processing speed, attention and learning and memory, and a subjective cognitive measure. The primary outcome measure was change from baseline to week 8 in a composite z-score comprising the Digit Symbol Substitution Test (DSST) and Rey Auditory Verbal Learning Test (RAVLT) scores. Depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). In the pre-defined primary efficacy analysis, both doses of vortioxetine were significantly better than placebo, with mean treatment differences vs. placebo of 0.36 (vortioxetine 10 mg, p < 0.0001) and 0.33 (vortioxetine 20 mg, p < 0.0001) on the composite cognition score. Significant improvement vs. placebo was observed for vortioxetine on most of the secondary objectives and subjective patient-reported cognitive measures. The differences to placebo in the MADRS total score at week 8 were −4.7 (10 mg: p < 0.0001) and −6.7 (20 mg: p < 0.0001). Path and subgroup analyses indicate that the beneficial effect of vortioxetine on cognition is largely a direct treatment effect. No safety concern emerged with vortioxetine. Vortioxetine significantly improved objective and subjective measures of cognitive function in adults with recurrent MDD and these effects were largely independent of its effect on improving depressive symptoms.
This paper references
10.1036/1097-8542.554800
Psychopharmacology
B. Pitt (1968)
10.2307/2529115
Statistical Power Analysis for the Behavioral Sciences
Jacob Cohen (1969)
10.1177/000348947108000408
References
(1971)
Food and Drug Administration Center for Drug Evaluation and Research
Holiday Inn Gaithersburg (1996)
Guideline for Good Clinical Practice
Ich Harmonised Tripartite Guideline (1996)
A randomized, double-blind, placebocontrolled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder
N Henigsberg (1996)
10.1016/S0924-9338(97)83296-8
The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI
Y. Lecrubier (1997)
10.1016/S0924-9338(99)80239-9
The mini international neuropsychiatric interview
Y. Lecrubier (1998)
From the Food and Drug Administration.
J. Samet (2002)
10.1007/s00213-002-1151-x
Acute administration of citalopram facilitates memory consolidation in healthy volunteers
C. Harmer (2002)
10.4088/JCP.V64N1211
The economic burden of depression in the United States: how did it change between 1990 and 2000?
P. Greenberg (2003)
10.1136/jnnp.2003.029074
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease
K. Rockwood (2004)
The role of the hippocampus in the pathophysiology of major depression.
S. Campbell (2004)
10.1177/070674370505000207
Finding Our Way: An Introduction to Path Analysis
D. Streiner (2005)
10.1177/0269881105051538
The effects of high-dose and low-dose tryptophan depletion on mood and cognitive functions of remitted depressed patients
L. Booij (2005)
The effects of high-dose and low-dose tryptophan depletion on mood and cognitive functions of remitted depressed patients. J A randomized, double-blind, placebo-... A randomized, double-blind
L Booij (2005)
Finding our way: an introduction to path analysis Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?
Streiner Dlpubmed (2005)
10.1111/j.1600-0447.2005.00626.x
Neuropsychological test profiles in schizophrenia and non‐psychotic depression
B. Rund (2006)
10.1016/j.psychres.2005.11.011
Neurocognitive deficits and disability in major depressive disorder
J. Jaeger (2006)
Neuropsychological test pro fi les in schizophrenia and nonpsychotic depression
BR Rund (2006)
Food and Drug Administration, Center for Drug Evaluation and Research. Memorandum on Suicidality. 16-Nov-2006
T Laughren (2006)
10.3760/CMA.J.ISSN.1007-9742.2007.06.106
Placebo
赵红彬 (2007)
10.1176/AJP.2007.164.6.900
Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
J. Raskin (2007)
10.1186/1471-244X-7-32
Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study
S. Naismith (2007)
10.1080/00048670601109881
Neuropsychological Impairment in Major Depression: Its Nature, Origin and Clinical Significance
R. Porter (2007)
10.1016/J.JPSYCHIRES.2007.09.004
Remission in depressed outpatients: more than just symptom resolution?
M. Zimmerman (2008)
10.1111/j.1600-0447.2008.01285.x
Mediators of the association between depression and role functioning
M. A. Buist-Bouwman (2008)
10.3389/neuro.09.026.2009
Cognitive Functioning in Major Depression – A Summary
Åsa Hammar (2009)
10.2174/157340009788971137
A Review of Modern Antidepressants' Effects on Neurocognitive Function
E. Biringer (2009)
10.1515/9783110208856.233
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009)
GO-TO;GO-TO;Go-To .
F. Madarasi (2009)
10.1007/s00213-010-1881-0
Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder
J. Murrough (2010)
10.1016/j.psychres.2008.12.001
The role of cognitive impairment in general functioning in major depression
B. Baune (2010)
Defining and measuring functional recovery from depression. CNS Drugs 24:267–284
TL Greer (2010)
Defining and measuring functional recovery from depression. CNS Drugs
TL Greer (2010)
De fi ning and measuring functional recovery from depression
TL Greer (2010)
Guidance for industry: suicidality: prospective assessment of occurrence in clinical trials
(2010)
Defining and measuring functional recovery from depression
Tl Greer (2010)
10.1021/jm101459g
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
B. Bang-Andersen (2011)
Stensbøl TB (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder
B Bang-Andersen (2011)
10.1124/jpet.111.189068
Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
A. Mørk (2012)
10.1016/S0924-977X(12)70363-2
P.2.b.005 The effects of the multimodal antidepressant Lu AA21004 on attention and vigilance measured as EEG activity in the rat
C. Sanchez (2012)
10.4088/JCP.11m07203
Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission?
M. Zimmerman (2012)
10.3109/08039488.2011.626870
Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?
A. M. Svendsen (2012)
10.1097/YIC.0b013e3283542457
A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder
C. Katona (2012)
10.4088/JCP.11m07470
A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
N. Henigsberg (2012)
10.1016/j.jad.2011.10.023
A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder.
R. Lee (2012)
10.1017/S1461145711001027
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
E. Alvarez (2012)
10.1002/da.21987
WHY DO SOME DEPRESSED OUTPATIENTS WHO ARE NOT IN REMISSION ACCORDING TO THE HAMILTON DEPRESSION RATING SCALE NONETHELESS CONSIDER THEMSELVES TO BE IN REMISSION?
M. Zimmerman (2012)
Why do some depressed outpatients who are not in remission according to the Hamilton depression rating scale nonetheless consider themselves to be in remission? Depress Anxiety
M Zimmerman (2012)
A double-blind, randomized, placebo-controlled, active-reference study of Lu AA21004 in patients with major depressive disorder (MDD)
E Alvarez (2012)
A randomized, doubleblind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder
C Katona (2012)
Why do some depressed outpatients who are not in remission according to the Hamilton depression rating scale nonetheless consider themselves to be in remission? Depress Anxiety 29:891–895
M Zimmerman (2012)
In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets
L Westrich (2012)
10.1017/S1092852913000345
Incentive salience: novel treatment strategies for major depression
D. Soskin (2013)
10.1017/S1092852913000540
Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction
A. Pehrson (2013)
10.1017/S0033291713002535
Cognitive impairment in depression: a systematic review and meta-analysis
P. Rock (2013)
10.1016/j.euroneuro.2012.04.006
Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—A rat microdialysis and electrophysiology study
A. Pehrson (2013)
10.1002/da.22063
COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS
Roger S. McIntyre (2013)
10.1016/j.pbb.2013.01.019
Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats
A. Mørk (2013)
10.1016/S0924-977X(13)70301-8
P.1.g.014 Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms
A. Pehrson (2013)
Vortioxetine’s (Lu AA21004) memory enhancing properties in preclinical rat models may involve an increase of pyramidal cell output – rat hippocampal slice study
E Dale (2013)
Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety 30:515–527
RS McIntyre (2013)
Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety
RS McIntyre (2013)
10.1016/j.euroneuro.2013.10.011
Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: Evidence for direct 5-HT receptor modulation
J. B. Jensen (2014)
10.1097/YIC.0000000000000018
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
J. Boulenger (2014)
10.1016/j.euroneuro.2013.07.001
Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism
K. G. D. Jardin (2014)
J Neurol Neurosurg Psychiatry
A randomized, double-blind, placebo-... A randomized, double-blind, placebo
Images in this article
Int J Neurop... PubMed Central, Fig. Int J Neurop
Efficacy study of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (FOCUS); NCT01422213
Clinicaltrials



This paper is referenced by
10.1186/s43045-021-00124-6
Alertness in patients with treatment-resistant depression: interface between sleep medicine and psychiatry—review article
D. Kolar (2021)
10.1016/j.pnpbp.2020.110088
Systematic review of gender bias in vortioxetine clinical trials
María Santos-Casado (2021)
10.1080/03007995.2021.1918072
Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess Patient Support Program
D. Lawrence (2021)
10.14744/DAJPNS.2021.00115
Vortioxetine: a comprehensive update on a new-generation antidepressant
C. Evren (2021)
10.1016/j.neuroimage.2021.117913
Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm
B. Spurny (2021)
10.3389/fpsyt.2021.635502
Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression
C. Segura-García (2021)
10.32648/2639-3298/3/1/001
Donepezil and α-synuclein Constipation: A 48 Month Follow-Up
C. Lepkowsky (2021)
10.2147/NDT.S288108
Relationship of Subjective Cognitive Impairment with Psychosocial Function and Relapse of Depressive Symptoms in Patients with Major Depressive Disorder: Analysis of Longitudinal Data from PERFORM-J
T. Sumiyoshi (2021)
10.3389/fphar.2021.728725
Erythropoietin and Non-Erythropoietic Derivatives in Cognition
S. S. Newton (2021)
10.12740/PP/ONLINEFIRST/132496
Pharmacological treatment of a depressive episode and recurrent depressive disorder - guidelines of the Polish Psychiatric Association and the National Consultant for Adult Psychiatry.
J. Samochowiec (2021)
10.1016/j.pnpbp.2020.110036
Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression
Yan Bi (2021)
10.3389/fpsyg.2021.628416
Cognitive Control, Cognitive Biases and Emotion Regulation in Depression: A New Proposal for an Integrative Interplay Model
D. Villalobos (2021)
10.1038/s41598-021-88462-7
Vortioxetine ameliorates anhedonic-like behaviour and promotes strategic cognitive performance in a rodent touchscreen task
L. Martis (2021)
10.1007/978-3-030-70135-2_7
Clinical Management of the Homeless Patient with Traumatic Brain Injury and Cognitive Impairment
Bruno S. Subbarao (2021)
10.3389/fimmu.2021.677879
Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models
Eleni Stamoula (2021)
10.1186/s12888-021-03094-5
Conditional power of antidepressant network meta-analysis
L. Holper (2021)
10.1177/2045125320943399
Usefulness of vortioxetine noted in depression secondary to hypoxic brain injury and residual cognitive deficits
S. Ahsan (2020)
10.1016/S0140-6736(20)31544-0
Bipolar disorders
R. McIntyre (2020)
10.1192/bjo.2020.114
Baseline predictors of cognitive change in the treatment of major depressive episode: systematic review
Zoe A Barczyk (2020)
10.1017/S109285292000173X
Effect of Vortioxetine in Subjects with Major Depressive and Alcohol Use Disorders: A Six-Months Retrospective Analysis.
M. Di Nicola (2020)
10.25040/lkv2020.03.046
Characteristics of Executive Functions in Patients With Cognitive Impairments in the Presence of Depressive Disorders
S. Yaroslavtsev (2020)
10.5455/pcp.20200320081142
Skin Reaction Associated With Vortioxetine: Purpuric Rash
D. Yıldız (2020)
10.1016/B978-0-12-819641-0.00105-5
Antidepressant Drugs: Mechanisms of Action and Side Effects
Jane Pei-Chen Chang (2020)
10.1111/jcpt.13177
Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double‐blind randomized trial
Firouzeh Borhannejad (2020)
10.1007/s00604-020-04523-0
Synthesis of three-dimensional nickel ferrite nanospheres decorated activated graphite nanoplatelets for electrochemical detection of vortioxetine with pharmacokinetic insights in human volunteers
Mater H. Mahnashi (2020)
10.1016/j.pnpbp.2019.109777
Meta-analysis of placebo group dropout in adult antidepressant trials
Fenghua Li (2020)
10.1080/14737167.2021.1855979
Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant
K. Atsou (2020)
10.30773/pi.2020.0017
Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial
C. Shin (2020)
10.1038/s41380-020-0727-3
Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders
T. Prevot (2020)
10.1186/s13063-020-04460-6
Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial
G. Ostuzzi (2020)
10.1007/s00213-020-05452-9
Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice
Li-xin Jiang (2020)
10.1016/j.psychres.2020.112767
Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder
Caroline Park (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar